-
9 Notable Biotechs Presenting At This Year's ASH Meeting
Monday, November 6, 2017 - 5:31pm | 1142Read More...One of the biggest biotech conferences of the year is around the corner. The 59th annual meeting of the American Society of Hematology, or ASH, is Dec. 9-12 in Atlanta. It's likely to serve as a make-or-break catalyst for many companies researching blood-related diseases and disorders. About 3,...
-
Benzinga's Bulls And Bears For The Past Week: Disney, GE, Tesla And More
Saturday, September 9, 2017 - 4:50pm | 614Read More...Benzinga has featured a look at many investor favorite stocks over the past week. Bearish calls included an iconic industrial and a popular consumer products maker. Bullish calls featured a media giant and the leading EV producer. From the holiday last week to the hurricanes, forest fires and...
-
BTIG Comments On Bluebird Bio's Q1 Print, Highlights Future Catalysts
Thursday, May 5, 2016 - 3:07pm | 264Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) were trading lower by 5 percent mid-Thursday afternoon after the company reported its first-quarter results. Bluebird bio said that it lost $1.52 per share on revenue of $1.499 million during the quarter. Wall Street analysts were expecting the company to...
-
Bluebuird Bio Crashes Nearly 30%: What's Next?
Monday, December 7, 2015 - 11:53am | 1162Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) plunged nearly 30 percent Monday morning. Bluebird reported mixed results from its ongoing studies at an industry conference. Matthew Harrison of Morgan Stanley acknowledged he "took a swing and missed," but other top Wall Street pros...
-
Roth Says Buy The Dip In This Biotech
Friday, August 7, 2015 - 9:47am | 269Read More...Since it hit a 52-week high on May 29, bluebird bio Inc (NASDAQ: BLUE) is more than 18 percent lower. Debjit Chattopadhyay, an analyst with Roth Capital Partners, said that given this correction, it is now time to buy the dip. Heading into the American Society of Hematology meeting in Q4, Roth...
-
Bluebird Bio's Positive LentiGlobin Data: Wall Street Responds
Monday, June 15, 2015 - 11:35am | 353Read More...Shares of bluebird bio Inc (NASDAQ: BLUE) were rallying in Monday’s pre-market session, spiking over 5 percent before falling back down to the $180 range by mid-day. The catalyst for the spike was due to encouraging results of an experimental gene therapy product called LentiGlobin...
-
Biogen Or Bluebird: Which Will Lead In SCD?
Thursday, April 30, 2015 - 12:42pm | 428Read More...On April 29, Joshua Schimmer of Piper Jaffray released a report highlighting several biopharmaceutical companies tackling Sickle Cell Disease, or SCD. The hereditary blood disorder is recognized by abnormal hemoglobin in the blood. Schimmer believes that to cure SCD with gene therapy, only...
-
LifeSci Capital's Andrew McDonald On How To Invest In Booming Biotech
Friday, April 17, 2015 - 2:56pm | 1016Read More..."Biotech is booming," says LifeSci Capital co-founder and co-manager of the BioShares exchange traded funds, Andrew McDonald. McDonald, along with fellow LifeSci co-founder Paul Yook, spoke with Benzinga about innovations in biotech and how investors might take advantage. BZ: What...
